Fig. 1

ZFP64 expression is increased in human GC tissues and prominently expressed in nab-paclitaxel-resistant GCs. A Heatmap illustrating the differentially expressed genes based on the RNA-sequencing data from GC tissues and surrounding normal tissues. B Venn diagram showing the number of overlapping genes that were differentially expressed between four paired GC tissues or surrounding normal tissues. C Heatmap illustrating the differentially expressed genes between nab-paclitaxel-sensitive and nab-paclitaxel-resistant GC tissues. D ZFP64 levels in nab-paclitaxel-sensitive (n = 2) and nab-paclitaxel-resistant (n = 2) GC tissues was examined by western blotting. E qRT-PCR analysis of ZFP64 mRNA in GC tissues (T) and corresponding normal tissues (P) from the Zhongshan cohort (n = 20). F Western blot analysis of paired human GC samples (left panel) and quantified by using ImageJ software (right panel). G-H IHC staining for ZFP64 was performed on a human GC tissue microarray (G) and quantified by using Image-Pro Plus software (H). Scale bars, 50 μm. I Overall survival curve for patients with low or high ZFP64 expression (P = 0.039). J Forest plot of significant factors associated with OS in GC patients. Data are presented as the means ± SEM. **P < 0.01; *** P < 0.005. ZFP64, Zinc Finger Protein 64; IHC, immunohistochemistry; GC, gastric cancer; OS, overall survival; qRT-PCR, quantitative reverse transcription PCR